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Abstract 
Research into non-hormonal, alternative therapies is necessary for women for whom menopausal 
hormone therapy is contraindicated or for women who do not wish to take hormones. This review 
focuses on one such non-hormonal option, namely, purified and specific cytoplasmic pollen extract, 
or PureCyTonin®. This extract has been evaluated in several preclinical and clinical studies, where 
it demonstrated its value as a safe and non-estrogenic alternative for menopause. This review 
presents the beneficial effects of PureCyTonin® in the treatment of menopausal symptoms (e.g. hot 
flushes) in healthy women, as well as in premenstrual syndrome. We discuss the mechanism of 
action of PureCyTonin®, an SSRI-‘like’ therapy. The lack of estrogenic effect demonstrated in 
preclinical studies suggests that PureCyTonin® may also be a suitable option for the management of 
menopausal symptoms in women with breast cancer. 
摘要 
非激素替代疗法的研究对于绝经期激素治疗禁忌的妇女或不希望服用激素的妇女是必要的。
这篇综述着重介绍了一种非激素的选择, 即纯化和特异性细胞质花粉提取物或PureCyTonin®
。此提取物已经在多项临床前和临床研究中被评估, 并证明了其作为绝经期安全且无雌激素
替代品的价值。这篇综述介绍了PureCyTonin® 在治疗健康女性绝经期症状(如潮热)以及经前
综合征方面的有益作用。我们讨论了PureCyTonin® 的作用机制, 这是一种类似SSRI的疗法。
临床前研究表明, PureCyTonin® 缺乏雌激素作用可能也是治疗乳腺癌女性绝经期症状的合适
选择。 
The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics 
and Gynecology Hospital, Capital Medical University, Beijing 100026, China. 
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Introduction 
The life expectancy of women in developed countries has increased by more than 30 years during 
the last century. Consequently, menopause has become a natural event in a woman’s life. 
Menopause is characterized by loss of reproductive function and decline in estrogen levels [1,2] and 
may be associated with multiple symptoms such as hot flushes, night sweats, sleep disturbances, 
decreased libido, sexual dysfunction, poor memory, anxiety/depression, and urinary incontinence, 
all of which may constitute indications for therapeutic intervention. Hot flushes are a 
thermoregulatory disorder due to a lack of estrogens. They are the most characteristic and 
distressing symptoms of menopause and have been reported to affect over 75% of middle-aged 
women [3]. Menopausal hormone therapy (MHT) is an established and effective option for hot 
flushes in menopausal women. However, it is contraindicated in conditions such as estrogen-
dependent diseases and acute thromboembolic events. Adherence to hormone therapy is frequently 
not satisfactory. Since the primary and negative outcomes of the large-scale US clinical trial MHT 
of the Women’s Health Initiative (WHI) Study in 2002, the number of MHT prescriptions has 
dropped drastically. 
While regulatory bodies in Europe and the USA recommend that MHT should be used for as short a 
time as possible, some clinical guidelines recommended less restrictive prescribing. However, for 
women for whom MHT is contraindicated or who do not wish to take hormones, research into 
alternative therapies is clearly necessary. These include non-hormonal options, which may be non-
pharmacological or pharmacological. Non-pharmacological interventions include lifestyle changes, 
behavioral therapies, holistic techniques, food supplements, and herbal therapies [4]. 
Pharmacological interventions include anti-depressants, anti-hypertensive drugs, and anti-epileptics 
[5,6]. 
This review focuses on PureCyTonin®, which is the main ingredient of the food supplement 
Serelys®. Serelys® is natural in origin and constitutes a non-hormonal alternative for the treatment 
of hot flushes and other menopausal symptoms. Its value and safety in the treatment of menopausal 
hot flushes and in premenstrual syndrome (PMS) has been demonstrated in several preclinical 
in vitro and in vivo studies and in clinical trials. 
Background 
Pollen (from the Greek ϖάλη [pale]: flour or dust) constitutes the male gametophyte of the flower. 
It is composed of minuscule ovoid grains measuring 20–55 µm in diameter that are initially 
contained at the end of stamens and are surrounded by a shell called an exine. The function of this 
pollen shell is to protect the genetic material. Well-known allergens are located on the external 
shell, whereas the center of the pollen contains the cytoplasm [7]. Germination occurs when the 
pollen is transported by wind or bees to a compatible female pistil. The male gametophyte produces 
a pollen tube that transfers the sperm to the egg, which contains the female gametes. Pollen has long 
been used for therapeutic purposes by various civilizations (e.g. Ancient Egypt and China, as far 
back as 200 BC). The chemical composition of pollen depends largely on the plant source and 
geographic origin, together with factors such as climatic conditions, soil type, and the activity and 
race of the bees. However, since pollen may be of unspecific origin (from unknown plants) and may 
be mixed with other bee products, standardization is difficult [8]. In addition, when the grain is 
unopened, its components can be partially assimilated because the pollen shell cannot be damaged 
by stomach acid [9,10]. The shell proteins are meant to be highly allergenic [9,10]. Gôsta Carlsson, 
a Swedish gynecologist, is considered the ‘father’ of the pollen extraction method. In the 1940s, he 
took an empirical approach to this field, with the hypothesis that the administration of pollen 
extracts could return strength and vigor to elderly patients. 
Production of purified and specific cytoplasmic pollen extract: 
PureCyTonin® 
Today, the extraction procedure for purified and specific cytoplasmic pollen extract under the 
trademark of PureCyTonin® (removed from its allergenic shell) enables retention of the active 
pollen components. PureCyTonin® is the main ingredient of the food supplement Serelys®, which is 
a combination of purified pollen/pistil cytoplasmic extracts. The pollen and pistils come from 
selected plants belonging to the Gramineae family and/or Pinaceae family and are harvested 
separately using a standardized method. Cultivation and harvesting take place in fields that are 
separated by plant type in accordance with the recommendations of the European Medicines 
Agency. The fields are free of pesticides and the chemical molecules usually used for plant growth 
and of any possible contamination. Manufacture of PureCyTonin® includes procedures that destroy 
the allergenic components of pollen. Allergens are broken down into peptides and amino acids. In 
the process, the pollen shells are completely removed, thus minimizing the risk of allergic reactions. 
The production procedures are standardized to ensure that batches of cytoplasmic pollen extract are 
reproducible. High-performance liquid chromatography (HPLC) and gas chromatography can verify 
that the group of compounds which forms the active substance is consistent between each batch. 
These extracts contain entities such as proteins, amino acids, sugar, minerals, vitamins, and fats. 
The amino acids, in particular, can be identified using analytical methods. Tryptophan, a precursor 
of serotonin, has been documented to be present in the pollen of the plants from which 
PureCyTonin® is extracted [11]. 
The method described makes it possible to exclude any allergen, thus ensuring that PureCyTonin® 
is safe to use. In addition, the exclusion of the shell, which constitutes a very stable protective 
pollen wall, makes the active compounds highly bioavailable [9,10]. Pollen extracts are water-
soluble, and several compounds in the water-soluble pollen extracts are suitable. These include 
nutrients such as amino acids, carbohydrates, and minerals, as previously described [9,10]. 
However, no specific PK/PD data are available, and further studies should be performed. With a 
standardized extract blending procedure, 160 mg of PureCyTonin® and pollen/pistil extract is the 
main component of Serelys®, with a recommended daily dose of 320 mg. Serelys® has been used in 
Europe since at least 1995. A search on PubMed reveals a variety of commercial names: Serelys®, 
Femal®, Femalen®, Femelis Meno®, Menolesse®, Sansage®, and Relizen®. In France, it has received 
marketing authorization, under the name of Femelis, as a traditional herbal medicine used to relieve 
the symptoms of the menopause. 
Preclinical studies with purified and specific cytoplasmic 
pollen extract: PureCyTonin® 
PureCyTonin® has been evaluated in several preclinical studies, where it demonstrated its value as a 
safe and non-estrogenic alternative for menopausal symptoms (Table 1). 
Table 1. In vitro and in vivo analysis with purified and specific cytoplasmic pollen 
extract: PureCyTonin®. 
CSVDisplay Table 
PureCyTonin® has been tested for acute oral toxicity. It was given to 10 mice at a single dose of 
2000 mg/kg. The mice were followed for 2 weeks. All the animals survived, with no signs of 
toxicity, thus indicating that PureCyTonin® is very safe and nontoxic when given orally at a single 
high dose to these animals [12,13]. 
An OECD-approved genotoxicity test (the Ames test) has also been performed with PureCyTonin® 
to determine potential mutagenic activity. The Ames test uses bacteria to test whether a given 
product can cause mutations in the DNA of the test organism. It therefore serves as a quick and 
convenient assay to estimate the carcinogenic potential of a compound. The potential of 
PureCyTonin® for inducing reverse gene mutations has been examined, although no mutagenic 
activity was observed when the product was assessed using the Ames test [14,15]. A non-mutagenic 
extract is generally considered to have no carcinogenic potency and does not need to be further 
investigated for carcinogenesis. 
Several in vitro and in vivo tests demonstrated that PureCyTonin® has no estrogenic action. A 
detailed study of the phytoestrogen composition by HPLC analysis revealed no trace of genistein, 
formononetin, or biochanin A, although it did show very minimal sub-effective concentrations of 
daidzein and genistein in these pollen extracts, thus ruling out any estrogenic action of pollen 
extracts. 
Compared with ethinyl estradiol, PureCyTonin® did not show any uterotrophic effect in immature 
female rats when the uterotrophic screening assay was applied in juvenile Wistar rats [16]. No 
estrogenic effect was demonstrated in a reporter gene assay using human embryonic kidney 293T 
cells that were co-transfected with estrogen receptors ER alpha and ER beta and a luciferase 
reporter plasmid containing ER response elements. Compared with 17-b estradiol, PureCyTonin® 
was not able to induce transcriptional activation through the estrogen receptors [17]. 
The human breast cancer cell line MCF7 endogenously expresses estrogen receptors and has been 
widely used for the study of estrogenic compounds. These cells were used to test whether an 
estrogenic effect of pollen extract led to proliferation. PureCyTonin® did not show any effect on 
cell proliferation in MCF7 cells up to the highest concentration tested [17]. 
Recently, PureCyTonin®, was analyzed to determine whether a small breast cancer risk may exist 
by stimulating steroidal receptors other than nuclear estrogen receptors, such as progesterone 
receptor membrane component (PGRMC1). Receptor membrane-initiated actions of PureCyTonin® 
were compared with estradiol (E2) and growth factors (IGF, FGF, EGF) in two different breast 
epithelial cancer cells (MCF7 and TD47) transfected with PGRMC1. The response of hormone 
receptor-positive breast cancer cells to estradiol (E2) and growth factors took the form of an 
increased proliferation rate and downregulation of apoptosis. PureCyTonin® was neutral in the cell 
lines transfected or not transfected with PGRMC1 in terms of cell proliferation and cell apoptosis 
compared to estradiol and growth factors. It was also neutral in combination with estradiol and 
growth factors in the two parameters tested. The authors conclude that the reduction in symptom 
scores reported from postmenopausal women treated with Serelys® may not be mediated by 
estrogen or estrogen-like pathways [18]. PureCyTonin® did not interfere with the efficacy of 
tamoxifen since it does not inhibit CYPD26, the enzyme which metabolizes tamoxifen to its active 
metabolite [19]. 
The data set out above support those reported by Espié [17] and recently by Biglia et al. [20] and 
Capozzi and Lello [21], who concluded that pollen extract is a non-estrogenic alternative for 
managing menopausal symptoms in cancer survivors. 
Serelys® in menopause: clinical data 
Serelys® has proven efficacious for the treatment of vasomotor symptoms in several clinical trials, 
including placebo-controlled trials, a clinical trial comparing treatment with MHT, and open-label 
studies (Table 2). 
Table 2. Clinical trials with Serelys® in menopause. 
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A randomized double-blind placebo-controlled study showed a significant reduction in hot flushes 
compared with placebo after 3 months. A total of 64 menopausal women were monitored during an 
initial phase of 1 month, during which their menopausal symptoms were recorded. This phase was 
followed by a 3-month period in which one group received Serelys® (at a rate of two tablets per 
day), while the other group received placebo. Sixty-five percent of women treated with Serelys® 
responded with a reduction in hot flushes compared with 38% in the placebo group (p < .006). In 
the Menopausal Rating Scale (MRS) evaluation, there was a 23% reduction in hot flushes in women 
taking Serelys® compared with placebo after 2 months. The reduction was 22% after 3 months. 
There was also an improvement in tiredness, dizziness, mood, libido, headache, irritability, mood 
swings, and sensitiveness in the Serelys® group compared with baseline (p < .031) [22]. 
In the same study, no differences were found in the hormone profiles of the two treatment groups, 
both of which had the expected high levels of FSH and low levels of estrogen. In addition, there 
were no changes in the level of SHBG or testosterone [22]. 
An open study conducted in France with 417 women taking Serelys® for 3 months showed an 
improvement or reduction in menopausal symptoms. The frequency of hot flushes was reduced by 
65% (intensity by 64%), sweating and perspiration by 66% (intensity by 67%), irritability by 54%, 
and fatigue by 51%. Quality of life and tolerance were considered excellent in perimenopausal and 
menopausal women [23]. 
In a subanalysis, perimenopausal and menopausal women were assessed separately for tolerance 
and effectiveness of Serelys®. Serelys® proved to be very efficacious in many of the parameters 
analyzed, and tolerance was excellent in 92% of the patients [24]. In another study, standardized 
pollen extract was associated with an improvement in perimenopausal symptoms such as hot 
flushes and mood swings [25]. 
D’Alterio et al. [26] showed benefits for peri- and post-menopausal neurovegetative symptoms in a 
clinical trial where women were treated with Serelys®, estrogen/progestin therapy, or placebo for 
6 months. This study confirmed efficacy in reducing the intensity of the neurovegetative symptoms 
of menopause. The reduction in the Kupperman index was slightly lower, but similar to that of 
estrogen/progestin therapy. 
Quality of life and reduction in hot flushes were recently assessed in Poland in an open-label study 
that demonstrated efficacy with respect to the resolution of vasomotor symptoms after as few as 
4 weeks of treatment; this effect increased during the subsequent months as well. The benefits of 
Serelys® in perimenopausal women are multidirectional in nature and pertain to many somatic and 
nonsomatic elements responsible for the quality of life [27]. 
A prospective observational study to evaluate the efficacy and safety of Serelys® in the 
management of women with menopausal symptoms was performed in 104 women in the Czech 
Republic. This study showed a significant decrease in various menopausal symptoms from baseline 
through 12 weeks (p < .0001). Hot flushes were reduced by 48.5%, sleep disturbances by 50.1%, 
depressive mood by 51.2%, irritability by 47.9%, and fatigue by 47.8%. Menopausal symptoms 
were reduced significantly, with very few side effects [28]. 
Taken together, these data show that PureCyTonin® is an effective non-hormonal, non-
pharmacological therapy for the management of hot flushes and menopausal symptoms. Compared 
with non-pharmacological interventions and other non-hormonal treatments, it is effective and safe 
in women who do not wish to take MHT and women for whom MHT is contraindicated, e.g. 
women with breast cancer who turn to natural supplements and remedies for relief. 
In the 2015 position statement of the North American Menopause Society on non-hormonal 
management of menopause-associated vasomotor symptoms, pollen extract was already classified 
as ‘Over-the-counter supplements and herbal therapies’. However, in this position statement, only 
one randomized controlled trial in menopause was evaluated [6,22]. In France, marketing 
authorization has been granted under the name Femelis as a traditional herbal medicine used to 
relieve the symptoms of menopause. 
Although PureCyTonin® is not yet universally approved according to the main guidelines, the 
studies documented in this review point to PureCyTonin® as a non-estrogenic alternative for 
managing menopausal symptoms. It can also be administered in cancer survivors. The purpose of 
this review is to improve the quality of care by generating and disseminating information on pollen 
extract that can help to diversify professional practices. Therefore, PureCyTonin® and the finished 
product, Serelys®, could be recommended in the guidelines of the main gynecological societies as a 
non-hormonal alternative for the management of menopausal symptoms and to improve patients’ 
quality of life. 
Clinical data on Serelys® in premenstrual symptoms 
Premenstrual syndrome often includes symptoms such as anxiety, irritability, depression, loss of 
confidence, mood swings, and fatigue. There are also physical symptoms, typically bloating, water 
retention, and breast pain. It is the timing, rather than the types of symptoms, and the degree of 
impact on daily activity that supports a diagnosis of PMS. The symptoms, which may severely 
affect quality of life, occur during the 2 weeks before menses, and some signs continue during 
menstruation before disappearing a few days afterwards [29]. These manifestations can occur in 
women from their late 20s to their early 40s and have a negative impact on their professional, 
social, and sexual lives. PMS is caused by changes in normal hormone levels that can induce 
disorders in the central neuroendocrine system. It is well established that serotonin plays a role in 
PMS, as some selective serotonin reuptake inhibitors (SSRIs) have a beneficial impact on 
premenstrual disorders. A meta-analysis of all available randomized controlled trials involving 
SSRIs used in PMS confirmed these to be more efficacious than placebo [30–32]. 
PureCyTonin® has been proven to be beneficial for the management of PMS in various randomized, 
double-blind, placebo-controlled clinical trials (Table 3). One randomized double-blind placebo-
controlled cross-over trial showed the efficacy of Serelys® in women with PMS. The study included 
32 women. Group A received two Serelys® tablets twice daily for two consecutive cycles, whereas 
group B received placebo for two cycles. Groups A and B were then crossed over: those taking the 
placebo took the active product, and vice versa. Two months of active treatment lowered overall 
symptom indices significantly and lowered six of nine individual symptom scores by 27–57%. 
Symptoms (e.g. irritability, swelling, weight fluctuation, and mood swings) improved significantly 
in women with PMS when they took the active product (p < .05). Evidence for a slow onset of 
action and protracted effect was provided by the finding that all symptom indices studied declined 
significantly (by 48–88%) in the group that received placebo before active treatment (p < .01). 
Premenstrual weight gain was reduced by 50% in patients receiving active treatment compared with 
placebo. There were no reported unwanted or adverse effects during active treatment [33]. 
Table 3. Clinical trials with Serelys® in premenstrual symptoms. 
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Another randomized double-blind placebo-controlled multicenter trial looked at the efficacy of 
Serelys® in PMS: 50 women taking two tablets of the active product per day were compared with 
51 women on placebo. The study duration was four cycles. Compared with placebo, Serelys® was 
associated with a significant improvement in PMS symptoms, particularly in sleep disturbances. 
This reduction was further observed in women who reported irritability as their major PMS 
symptom (p < .001). There were no differences in adverse events in the active treatment group 
compared with placebo [34]. 
Winther et al. [35] confirmed these results in a recent sub-analysis in which women with PMS 
symptoms were separated depending on whether the predominant symptom was irritability or 
dysphoria. The authors showed that in patients reporting irritability as their main PMS symptom, 
Serelys® significantly lowered PMS indicators, as reflected in global scores in both observer-based 
and self-evaluation scoring of symptoms. 
Mechanism of action of Serelys® 
During the menopause transition, neuronal cells, neurotransmitters, neuropeptides, and 
neurosteroids in the central nervous system (CNS) undergo important changes as a consequence of 
fluctuations in the levels of hormones such as estrogen [36]. These changes could be responsible for 
the generation of hot flushes and modifications in behavior, cognition, and mood. There is evidence 
of a neuroendocrine origin and a key role of neurotransmitters (e.g. glutamate, gamma-
aminobutyric acid (GABA), serotonin (5-hydroxytryptamine [5-HT]), dopamine, acetylcholine 
noradrenaline), since some of the known treatments for hot flushes and modifications in behavior, 
cognition, and mood are compounds that modulate these neurotransmitters [37,38]. SSRIs are used 
for their known effect on thermoregulation and sleep quality, by acting on serotonergic neurons. 
Recently, a specific type of neurons – KNDy kisspeptin/neurokinin B/dynorphin neurons – have 
been shown to be present in the hypothalamus at the level of the preoptic area. These change 
dramatically in postmenopausal women, in whom they can generate hot flushes [39]. In this 
subpopulation of neurons, in particular, neurokinin B and its receptor NK3R have been implicated 
in the induction of hot flushes in healthy women that are typical in location and duration of 
postmenopausal hot flushes [40,41]. In order to gain more insights into the mechanism of action of 
Serelys® on neurons, the effect of PureCyTonin® on the uptake of [3H]-serotonin into rat cortical 
synaptosomes was analyzed. PureCyTonin® inhibited the uptake of [3H]-serotonin into rat cortical 
synaptosomes in a dose-dependent manner. The EC50 value of 60 µg/ml is well within a 
physiologically achievable order of magnitude. Inhibition of serotonin uptake may therefore play a 
role in the physiological action of Serelys® [42]. PureCyTonin® could act as an SSRI-like therapy, 
potentially without the known adverse effects of SSRIs. Additionally, tryptophan, a precursor of 
serotonin, is present in the pollen of the plants from which PureCyTonin® is extracted [11]. The 
average level of tryptophan in pollen extracts measured in Serelys tablets is about 0.09 mg/tablet 
[43]. Taking these observations together, pollen extract appears to maintain the availability of 
serotonin in hypothalamic serotonergic neurons, and this could explain in part the efficacy of the 
extract in controlling thermoregulation, sleep, and mood in menopausal women. There are also 
dopaminergic neurons located in the frontal cortex, the nucleus accumbens, the hippocampus, and 
the striatum. These dopaminergic neurons are responsible for pleasure, mood, motivation, and 
perseverance [44]. Decreased levels of estradiol in postmenopausal women may reduce 
dopaminergic neurotransmission and impair cognitive and motor functions [45]. 
A genomic study was performed in neurons to further investigate which pathways are modulated by 
PureCyTonin® and better understand its correlation with beneficial biological effects [42]. The 
human cell line SH-SY5Y, which comprises cells differentiated by all-trans-retinoic acid (RA), has 
long been used to study neuronal signaling pathways modulated by chemical entities. RA treatment 
induces differentiation of these proliferating cells to cells with a cholinergic neuron phenotype 
exhibiting neuron-like properties, including neurite, and expressing cholinergic neuronal markers. 
In this study, the cells were treated with or without PureCyTonin®, and mRNA extracted from SH-
SY5Y cells was analyzed with mRNA-seq profiling. Significantly modulated genes underwent 
pathway analysis using the software application Ingenuity Pathway Analysis (Qiagen, Germantown, 
MD) to identify pathways of interest that could be modified by pollen extract. Preliminary results 
show several modulated genes that may correlate with the beneficial effects induced by 
PureCyTonin® in menopausal women. These include the dopamine D2 receptor (DRD2), which 
was significantly modulated [42]. DRD2 is implicated in several domains, including motivation, 
pleasure, cognition, memory, learning, and fine motor control, as well as in modulation of 
neuroendocrine signaling. Interestingly, it has been shown that estradiol activates the transcription 
of DRD2 in the frontal cortex and increases the level of DRD2 mRNAs. DRD2 declines 
substantially during a person’s lifetime, and animal studies have shown age-related reductions in 
dopamine release and dopamine markers in the cerebral cortex [46]. Decreased levels of estradiol in 
post-menopausal women may reduce the expression of D2 receptors, thus contributing to reduced 
dopaminergic neurotransmission and impairment of cognitive and motor functions. Hence, this 
increased expression in DRD2 induced by pollen extract may benefit menopausal women. Current 
analysis is focusing on other genes coding for neuropeptides implicated in nociceptive pain, 
cognition, feeding, and various regulatory processes (waking and sleep, mood, blood pressure, 
osmosis, and water intake). In one study, pollen extract increased the expression of protective 
enzymes such as NQO1, an antioxidant enzyme that exerts its effect by scavenging superoxide to 
shield against oxidative stress actuated by cytotoxic substances. This action could provide 
additional cytoprotection and prove especially effective in tissues with low levels of superoxide 
dismutase expression in pro-oxidant environments. It has been shown that the marked reduction in 
estrogen during menopause increases levels of oxidative stress in the body [47]. Part of the 
mechanism of action of PureCyTonin® could also be explained by its antioxidant activity. 
Compared with other approaches, pollen extracts have been shown to exhibit superoxide dismutase 
activity in the generation of oxygen free radicals [48]. 
Conclusions 
Serelys® is an effective and safe non-hormonal alternative for alleviating menopausal symptoms 
without increasing the risk of breast cancer in women in whom MHT is contraindicated or who do 
not wish to use hormones. Serelys® has proven to be safe and efficacious. It improves hot flushes, 
sleep disturbances, and nervousness in menopausal women. The beneficial effects are also observed 
in PMS. These findings seem to correlate with the effect of its main ingredient, PureCyTonin®, on 
inhibition of the reuptake of serotonin and other neurotransmitters. Current studies are being 
performed to fully determine the mode of action of PureCyTonin®. 
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